CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 17 enrolled
Drug / intervention
Lucentis (ranibizumab)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00500344
NCT00500344Phase 1Completed
CompareCT.gov

CAPTAIN: Choroidal Neovascularization Assessment by Pattern Electroretinography After Ranibizumab in Naive Age-related Macular Degeneration Patients

Washington University School of Medicine·interventional·Posted Jul 12, 2007·Updated May 3, 2018

In Brief

A Phase 1 clinical trial evaluating Lucentis (ranibizumab) for Age-related Macular Degeneration. Completed, enrolled 17 participants across 1 site.

Detailed Summary

CNV from AMD is the leading cause of blindness in people over 50 in North America. The hypothesis is to determine if there is an improvement in retinal function determined by ERG following treatment with ranibizumab for AMD

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge-related Macular Degeneration
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 12, 2007
Enrollment StartJul 1, 2007
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 19.0 years ago

Interventions

Lucentis (ranibizumab)drug

intravitreal injection